Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
BEARISH SIGNAL DETECTED · Alpha
██.█% Sign up free to reveal

Cogent Biosciences, Inc. (COGT) AI Forecast

Our AI ranks Cogent Biosciences, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$COGT Bearish Signal Full forecast available

Cogent Biosciences, Inc. (COGT) Stock Forecast Sept. 24, 2026


Cogent Biosciences, Inc. (COGT) AI Stock Price Forecast & Investment Analysis

Cogent Biosciences, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Cogent Biosciences, Inc. (COGT) - Comprehensive Stock Analysis & Investment Research

Deep dive into Cogent Biosciences, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 24, 2026 (UTC)

Cogent Biosciences, Inc. Investment Summary

When evaluating whether Cogent Biosciences, Inc. (COGT) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Cogent Biosciences, Inc. (COGT) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $5 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Cogent Biosciences, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Cogent Biosciences, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Cogent Biosciences, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Cogent Biosciences, Inc.

Sign Up Free
Corporate Identity

Cogent Biosciences, Inc. (Stock Symbol: COGT) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Cogent Biosciences, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Cogent Biosciences, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Cogent Biosciences, Inc....

Unlock Full Company Profile

Get complete details about Cogent Biosciences, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Cogent Biosciences, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Cogent Biosciences, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Cogent Biosciences, Inc....

Unlock Financial Analysis

Get complete financial metrics for Cogent Biosciences, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Cogent Biosciences, Inc.'s AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Cogent Biosciences, Inc. strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Cogent Biosciences, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-309 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Financial Strength & Leverage

Current ratio of 13.57 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Cogent Biosciences, Inc. (COGT) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Cogent Biosciences, Inc. stock analysis.

Deep dive into Cogent Biosciences, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Cogent Biosciences, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Cogent Biosciences, Inc.:

P/B Ratio 10.24x
Market Cap $5.45B
EPS $-2.15
Book Value/Share $3.07
FCF/Share $-1.78
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Cogent Biosciences, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Cogent Biosciences, Inc.: An ROE of -70.9% indicates room for improvement in shareholder value creation.

ROE -70.9%
ROA -45.2%
ROIC -50.2%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Cogent Biosciences, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Cogent Biosciences, Inc.: A current ratio of 13.57 indicates strong liquidity.

Current Ratio 13.57x
D/E Ratio 0.57x
Financial Leverage 1.57x
Interest Coverage -55.8x
Working Capital $746M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Cogent Biosciences, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Cogent Biosciences, Inc.: Free cash flow of $-309M indicates cash challenges that need attention.

Operating Cash Flow -$308M
Free Cash Flow -$309M
Capital Spending -$2M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Cogent Biosciences, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Cogent Biosciences, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Cogent Biosciences, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Cogent Biosciences, Inc.:

Income Statement
Operating Income -$389M
Net Income -$377M
R&D Expense $291M
Balance Sheet Highlights (USD millions)
Total Current Assets $805M (96.4% of assets)
Cash & Short-term Investments $181M (21.7% of assets)
Total Liabilities $302M (36.2% of assets)
Short-term Debt $52M (6.2% of assets)
Dividend & Shareholder Information
Shares Outstanding 174M

Latest Cogent Biosciences, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Cogent Biosciences, Inc. (COGT) stock price and investment outlook.

📰 Loading...

Where COGT sits on the market map

Explore the map →

Cogent Biosciences, Inc. Industry Peers - Pharmaceutical Preparations

Companies classified under the same SEC industry code as Cogent Biosciences, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
COGT ██% $5.45B x 10.2x
LLY ██% $1.08T 40.6x 110.2x
JNJ ██% $648.67B 30.8x 7.6x
ONC ██% $539.52B x 104.3x
ABBV ██% $468.43B 74.2x x
MRK ██% $365.34B 115.1x 8.7x
NVS ██% $272.31B x x
GSK ██% $214.26B x x
ABT ██% $180.26B 28.6x 3.5x
PFE ██% $160.62B 37.1x 1.9x
VRTX ██% $130.87B 29.7x 6.5x
BMY ██% $125.63B 13.5x 5.6x
REGN ██% $82.55B 19.1x 2.6x
SNY ██% $50.80B x x
TEVA ██% $45.46B 64.3x 5.9x
ALNY ██% $33.40B x 24.7x
RPRX ██% $33.15B 40.7x 4.9x
ATHE ██% $32.40B x x
TAK ██% $29.93B x x
ZLAB ██% $29.68B x 48.9x
ZTS ██% $29.59B 11.3x 9.4x
ROIV ██% $26.60B x 6.3x
INSM ██% $25.84B x 34.1x
UTHR ██% $20.99B 16.0x 3.3x
VTRS ██% $19.66B x x
JAZZ ██% $15.25B 16.2x 3.2x
ASND ██% $14.30B x x
SMMT ██% $13.12B x 20.8x
BBIO ██% $12.96B x x
CORT ██% $12.81B x 18.2x
HCM ██% $12.54B x 10.1x
BMRN ██% $11.88B x 1.9x
KNSA ██% $11.87B x 19.6x
MDGL ██% $11.85B x 22.6x
ELAN ██% $11.17B x 1.7x
RDY ██% $10.34B x x
AXSM ██% $10.27B x 123.3x
ARWR ██% $9.33B x 20.1x
CYTK ██% $9.13B x x
PTGX ██% $8.98B x 10.7x
PRAX ██% $7.88B x 5.9x
SYRE ██% $7.77B x 7.1x
GPCR ██% $7.71B x 5.7x
ABVX ██% $7.39B x x
IONS ██% $7.30B x 16.6x
ALKS ██% $6.84B x 3.8x
LEGN ██% $6.82B x x
RYTM ██% $6.76B x 65.7x
BLRX ██% $6.68B x x
BLTE ██% $6.67B x 8.7x
AMRX ██% $6.32B x x
LQDA ██% $6.04B x 31.0x
LGND ██% $5.95B 30.2x 6.2x
MIRM ██% $5.80B x x
AMRN ██% $5.64B x 12.7x
TVTX ██% $5.64B x 230.0x
PTCT ██% $5.20B x x
ERAS ██% $5.08B x 14.0x
DNTH ██% $5.07B x 4.3x
VKTX ██% $4.86B x 11.9x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Cogent Biosciences, Inc. Stock Forecast

How accurate are Cogent Biosciences, Inc. stock predictions?

A per-ticker accuracy statistic for COGT is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Cogent Biosciences, Inc. stock price forecasts?

Our analysis considers Cogent Biosciences, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Cogent Biosciences, Inc. a good investment in 2026?

Based on our AI analysis, Cogent Biosciences, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Cogent Biosciences, Inc. forecasts updated?

Cogent Biosciences, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 24, 2026.

Want a simpler view of Cogent Biosciences, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...